STRYKER CORP Q3 FY2026 earnings call

• Leadership Transition: CEO Kevin Lobo is departing after 57 quarters; Spencer Stiles has been appointed as the next CEO.
• Orthopedic Market Slowdown: A clear slowdown in hip and knee procedures observed in the US (due to affordability/deductibles) and Europe/Middle East (strikes/funding). The company was distracted by a Q1 cyber incident and July SAP implementation, delaying visibility and commercial execution for new products like Mako RPS and Triathlon Gold.
• Peripheral Vascular Recovery: Sequential improvement noted. Supply disruption is normalizing. One-time revenue boost from China JV regulatory milestone offset some losses. Expecting commercialization of AVS IVL platform and Peerless 2 data in 2027.
• Strategic Investments: Completed acquisition of Zeromini (sports medicine/arthroplasty soft tissue augmentation). Announced investment in CMR Surgical to act as exclusive US sales agent for Versys robotics, with an intent to eventually acquire the asset to de-risk entry into soft-tissue robotics.
• Innovation Pipeline: Strong upcoming launches including Neptune (instruments), System 10 (power tools), and 1888 (endoscopy). Mako Shoulder showing strong early success.
• Financial Discipline: Adjusted gross margin expanded 40 bps to 65.4%; adjusted operating margin expanded 60 bps to 26.2%. Expense discipline and operational efficiencies are mitigating the impact of sales shortfalls on EPS.

Med-Surg and Neurotechnology: Organic sales grew 9.1% (US: +9.6%, International: +7.2%). Key drivers included double-digit growth in interventional spine, surgical technologies, endoscopy (+13% US), and medical (+10% US). Instruments US organic sales grew only 4.8% due to capital deferrals ahead of the Sonopet 3 launch.

Orthopedics: Organic sales grew 5.9% (US: +6.4%, International: +4.4%). US hips declined 0.6% and US knees grew only 1.3% amid market slowdowns and execution distractions from SAP implementation. Conversely, US trauma/extremities grew 4.5% and OrthoTech surged 18% driven by Mako. Endoscopy and Medical divisions within this segment delivered strong double-digit performances.

• Q4 2026: Anticipates organic sales growth similar to Q3’s 7.7% rate, assuming continuation of current procedure environment and elevated capital demand.
• Full Year 2026 Revision: Revised full-year organic net sales growth guidance down to 6.5%–7.0% (previously higher) due to softer hip/knee trends, lingering vascular supply constraints, and capital equipment execution risks.
• EPS Guidance: Revised full-year adjusted EPS guidance to $14.80–$14.90, supported by margin expansion and expense discipline.
• 2027 Outlook: No formal numerical guidance provided yet. Management expects to deliver growth at the high end of their weighted average market growth estimates, targeting >6% company-wide growth if market conditions normalize.

• Market Headwinds: Slower procedural growth in hip/knee markets due to patient affordability concerns (high deductibles/premiums) and increased pre-authorization denials in the US; regional disruptions and funding issues in Europe/Middle East.
• Operational Execution: Distractions from Q1 cyber incident and ongoing SAP implementation delays in orthopedics, impacting new product adoption (Mako RPS, Triathlon Gold) and competitive conversion rates.
• Supply Chain: Ongoing peripheral vascular supply disruption, though inventory levels are expected to normalize through year-end.
• Competitive Pressure: Potential pricing pressure in orthopedics and new entrants in robotics (e.g., competitor monoblock robot), though management remains confident in Mako’s multi-application advantage.

Q: Robbie Marcus asked about the orthopedic market slowdown and its impact on margins. / A: CEO Kevin Lobo clarified that the slowdown is specific to hips and knees, not extremities, which remain high-growth. He attributed the delayed visibility to cyber/SAP distractions but noted historical precedent for recovery. CFO Preston Wells stated the weighted average market growth likely ticked down slightly from previous 6% estimates, but they aim to perform at the high end of that market in 2027. They expect margin improvements to continue via operational excellence despite joint replacement being a lower-margin segment currently.

Q: Larry Biegelsen asked why Stryker chose an investment/partnership model with CMR Surgical rather than an outright acquisition. / A: CEO Lobo explained that soft-tissue robotics is a high-risk, high-cost development area. By acting as exclusive US sales agent first, Stryker de-risks the venture while proving US commercial viability. He emphasized that CMR’s Versys Plus is modular and ideal for ASCs/hospitals, converting open/lap procedures. The plan is to eventually acquire the asset once US success is proven, similar to the Mako strategy but with less upfront financial risk.

Q: Joanne Wuensch asked what historically brings the hip/knee market out of slowdowns and how long recovery might take. / A: CEO Lobo linked past recoveries to economic cycles and patient ability to pay deductibles. As economic conditions improve, patients delay less until pain becomes unbearable. He stressed this is a temporary delay in degenerative disease treatment, not a disappearing market, but he cannot predict the exact timing of the snapback. CFO Wells reiterated they assume current conditions persist for guidance purposes.

Q: Ryan Zimmerman asked about Q4 growth drivers to offset ortho/vascular weakness and the state of capital demand. / A: CFO Wells highlighted that Trauma/Extremities, Medical (specifically Sage/SmartCare), and Instruments will drive Q4 strength. Peripheral vascular should show underlying improvement despite pressures. VP Nick Mead added that capital demand remains strong with an elevated order book, and the focus is on executing delivery capacity to meet this demand across all business units.

Q: Travis Steed asked if the ortho slowdown worsened in September and how the cyber incident impacts 2027 comps. / A: CEO Lobo stated things didn't worsen in September; rather, SAP delays prevented visibility until then. He distinguished between market slowdown (most of it) and lost share (minor, due to distracted teams). CFO Wells noted the cyber incident impacts will be spread out, with much recovery already realized, but anniversary effects will need tracking. CEO Lobo confirmed fundamentals remain strong despite the guide takedown.